The Hasan Program Project

Molecular Response and Imaging-based Combination Strategies for Optimal PDT

Themes and Integration

A central theme of the Program is the mechanism-based integration of PDT and optical imaging with other treatment modalities to provide, in its most ambitious form, patient-customized therapy. Molecular signatures of cancer are characterized by abnormal levels of specific molecules, such as receptors and proteins (synthesis and/or secretion) at the transcriptional or post-translational levels. Inhibitors of specific molecular pathways are emerging as promising cancer therapies and are viewed as suppressors of cellular or vascular growth and proliferation. These biological therapies are often cytostatic in nature and resistance to them ensues over time. The underlying thesis of this Program is that the best results in cancer treatment may be achieved by rational, mechanism-based combinations of cytotoxic therapies, such as PDT with biologic therapies, by which each modality augments the other. The augmentation may come from the modalities affecting different molecular targets or from the first modality priming the tumor cells for attack by the second. The augmentation may also come from phenotype alteration favoring PDT as a consequence of molecular manipulation such as differentiation.

The diagram above illustrates a simple representation of the integration of the Cores and Projects. The scientific theme of molecular mechanisms and response manipulation, combined with PDT and imaging, provides a commonality for all of the Projects. The Cores will provide one of the several integration mechanisms in the Program.


Project 1

Small Molecule Enhancers of Photodynamic Therapy for Skin Cancer

Project Leader: Edward Maytin, M.D. Ph.D.

The overall goal of this Project is to develop novel combination approaches to improve the response of skin cancer to ALA-mediated PDT (ALA-PDT) of NMSCs. To this end, we will test the overall hypothesis that biochemical and molecular signaling pathways, involved in the production of PS (PpIX) or in the regrowth of skin tumors, can be identified and exploited in a combination regimen with ALA-PDT, in a manner that will enhance the overall treatment response.


Project 2

Clinical Photodynamic Therapy for Pancreatic and Biliary Tract Cancer

Project Leader: Stephen P. Pereira, M.D. Ph.D.

The overall goal of this Project is to improve the survival and quality of life of patients with PanCa and BTC using PDT. This clinical Project involves a number of phase I/II and III studies in these cancers using two different PS, and derives from the preclinical work completed previously, as well as from early clinical studies of PDT in these malignancies by our group. Project 2 will collaborate closely with Project 4 and Core C on in vivo imaging techniques such as OCT, PS quantification using a single fibre, and imaging using multifibre applications.


Project 3

Mechanism-Based Design of Combination Therapies for PanCa

Project Leader: Tayyaba Hasan, Ph.D.

The overall goal of this Project is to develop mechanism-based PDT-combination treatments for PanCa to enhance the treatment efficiency of PDT in preclinical models. It is hoped that some of the new PDT-combination regimens developed in this Project will be transferred to the clinical Projects 1 and 2.


Project 4

Image-Guided and Model-Based Optical Dosimetry Tools

Project Leader: Brian W. Pogue, Ph.D.

The overall goal of this Project is to develop methods to quantify molecular features of tumors with optical measurements and to integrate these tools into standard clinical procedures in a way which facilitates the development and translation of novel cancer therapies. The research builds on both the previous funding period where PS quantification was a major part of the study and new findings on integrating multi-spectral tomography into standard imaging systems. The Project will leverage existing resources in optical tomography integrated into the 3T MRI as well as MicroCT and high frequency ultrasound (HFUS), and allow spatially-localized spectroscopy on small animal tumors.


If you are a patient or family member of a patient, please visit the Massachusetts General Hospital Cancer Center.

Please send questions or comments on this web site to Yupeng Tu.